Rapport Therapeutics Ownership | Who Owns Rapport Therapeutics?
Rapport Therapeutics Ownership Summary
Rapport Therapeutics is owned by 13.90% institutional investors, 4.71% insiders, and 81.39% retail investors. Trv gp v is the largest institutional shareholder, holding 2.01% of RAPP shares.
RAPP Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Rapport Therapeutics | 13.90% | 4.71% | 81.39% |
| Sector | Healthcare Stocks | 42.53% | 10.81% | 46.67% |
| Industry | Biotech Stocks | 45.24% | 10.75% | 44.01% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Trv gp v | 7.14M | 2.01% | $211.92M |
| Fmr | 6.92M | 1.95% | $205.43M |
| Arch venture management | 3.73M | 1.05% | $110.74M |
| Capital investors | 3.40M | 0.96% | $101.06M |
| Cormorant asset management, lp | 3.19M | 0.90% | $94.82M |
| Goldman sachs group | 2.42M | 0.68% | $71.93M |
| Sofinnova investments | 1.95M | 0.55% | $57.84M |
| Johnson & johnson | 1.78M | 0.50% | $53.00M |
| Vanguard group | 1.63M | 0.46% | $48.31M |
| Blackrock funding, inc. /de | 1.57M | 0.44% | $46.57M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Trv gp v | 7.14M | 59.95% | $211.92M |
| Trv gp vi | 969.22K | 26.26% | $28.79M |
| Arch venture management | 3.73M | 22.49% | $110.74M |
| Johnson & johnson | 1.78M | 10.52% | $53.00M |
| Cormorant asset management, lp | 3.19M | 6.54% | $94.82M |
| Sofinnova investments | 1.95M | 3.16% | $57.84M |
| Sio capital management | 185.26K | 1.39% | $5.50M |
| Vestal point capital, lp | 950.00K | 1.27% | $28.21M |
| Siren | 1.05M | 1.22% | $31.29M |
| Sphera funds management | 157.53K | 0.99% | $4.68M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 6.92M | 0.01% | 1.44M |
| Goldman sachs group | 2.42M | 0.01% | 1.19M |
| Baker bros. advisors lp | 1.55M | 0.33% | 997.00K |
| Vestal point capital, lp | 950.00K | 1.27% | 950.00K |
| Polar capital | 938.95K | 0.13% | 938.95K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Johnson & johnson | 1.78M | 10.52% | -713.53K |
| Price t rowe associates inc /md/ | 1.10M | 0.00% | -423.13K |
| Alliancebernstein | 855.62K | 0.01% | -299.07K |
| Logos global management lp | - | - | -208.91K |
| Affinity asset advisors | - | - | -199.64K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vestal point capital, lp | 950.00K | 1.27% | 950.00K | $28.21M |
| Polar capital | 938.95K | 0.13% | 938.95K | $27.89M |
| Adage capital partners gp | 450.00K | 0.02% | 450.00K | $13.37M |
| Perceptive advisors | 403.92K | 0.35% | 403.92K | $12.00M |
| Franklin resources | 250.59K | 0.00% | 250.59K | $7.44M |
Sold Out
| Holder | Change |
|---|---|
| Allworth financial lp | -15.00 |
| Parallel advisors | -50.00 |
| Us bancorp \de\ | -144.00 |
| Virtus etf advisers | -3.74K |
| Corebridge financial | -8.27K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 129 | 69.74% | 49,256,683 | 36.76% | 13 | 13.46% | 87 | 102.33% | 18 | 12.50% |
| Jun 30, 2025 | 80 | 5.26% | 38,487,484 | 29.20% | 10 | 15.22% | 45 | -15.09% | 18 | 100.00% |
| Mar 31, 2025 | 78 | 16.42% | 38,100,888 | 4.65% | 10 | 0.10% | 52 | 36.84% | 9 | -30.77% |
| Dec 31, 2024 | 68 | 25.93% | 36,575,839 | 28.91% | 104 | 1.57% | 39 | -4.88% | 13 | 85.71% |
| Sep 30, 2024 | 54 | 54.29% | 28,374,042 | 11.02% | 81 | 1.67% | 41 | 17.14% | 7 | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 17, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | $72.27K |
| Nov 17, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | $77.72K |
| Nov 17, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | $69.22K |
| Nov 17, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | $55.85K |
| Nov 17, 2025 | Bredt David | Chief Scientific Officer | Sell | $78.39K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 12 |
| 2025 Q3 | 4 | 10 |
| 2025 Q2 | - | 3 |
| 2025 Q1 | 3 | 1 |
| 2024 Q4 | - | - |
RAPP Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools